LNG-IUD + Semaglutide for Endometrial Cancer
(SWIFT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1 endometrioid endometrial cancer while preserving fertility in women of reproductive age with endometrial atypical hyperplasia (EAH) or FIGO grade 1 endometrioid endometrial cancer who wish to preserve their fertility. The main questions it aims to answer are:
* What proportion of participants achieve a complete pathological response after treatment?
* How durable is the response at 12 months?
* What effect does the treatment have on metabolic outcomes (weight, BMI, HbA1c) and quality of life?
Participants will:
* Receive an LNG-IUD
* Receive semaglutide 2.4mg
* Participate in a structured weight loss program
* Undergo hysteroscopy with endometrial sampling to assess treatment response
* Complete quality-of-life assessments at baseline, 6 months, and 12 months
Who Is on the Research Team?
Aparna A. Kamat, MD
Principal Investigator
The Methodist Hospital Research Institute
Are You a Good Fit for This Trial?
This trial is for women of reproductive age who have endometrial atypical hyperplasia or early-stage (grade 1) endometrial cancer and want to keep their ability to have children. Participants should also be overweight or obese.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- LNG-IUD
- Semaglutide
- Structured Weight Loss Program
Trial Overview
The study tests a combination of three treatments: a hormonal IUD (LNG-IUD), weekly semaglutide injections, and a structured weight loss program. The goal is to see if this approach can treat the condition while preserving fertility.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive a three-component combination intervention consisting of: (1) a levonorgestrel-releasing intrauterine device (LNG-IUD), inserted at baseline; (2) semaglutide 2.4 mg, administered per standard dosing schedule; and (3) a structured weight loss program. Participants will undergo hysteroscopy with endometrial sampling to assess pathological response. Treatment will be administered for 6 months of active intervention, followed by a 6-month follow-up period.
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Methodist Hospital Research Institute
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.